Introduction:

Diabetic foot is a clinical alteration of neuropathic etiopathogenic basis, induced by maintained hyperglycemia, in which, with or without coexistence of ischemia, as well as previous traumatic trigger, foot injury or ulceration is produced.

Objective:

To describe the outcomes of treatment with Heberprot-P® in patients with diabetic foot.

Methods:

Descriptive and prospective cross-sectional study carried out in patients with diabetic foot belonging to the Joaquín de Agüero y Agüero Polyclinic of Camagüey Municipality, during the period from July 2019 to July 2020. The study universe was made up of a total of sixty patients diagnosed with diabetic foot who were applied epidermal growth factor. The information was processed through the statistical package SPSS version 21.

Results:

Patients in the 65-74 years age group predominated (35 %), together with the female sex (58.8 %), as well as associated arterial hypertension (81.8 %). 38.4 % of diabetic patients presented with finger lesions of grade II (63.3 %) according to the Wagner's classification.

Conclusions:

With the application of Heberprot-P®, pain (78.3 %) appeared as an adverse effect. There was also total healing as a response to treatment (96.6 %), which permitted to maintain limb integrity.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )